Background and Objectives: Primary hyperparathyroidism (PHPT) is associated with an increased cardiovascular mortality and morbidity rate. However, the exact role of PTH and / or calcium in the development of cardiovascular disease (CVD) is still controversial. The infl uence of PHPT on hemostasis is yet unknown. Therefore, the main purpose of this study was to investigate the markers of endogenous coagulation / fi brinolysis and to evaluate the relationships between these hemostatic parameters, serum lipid profi le and serum calcium and PTH in patients with PHPT. Design and Methods: Twenty-three patients with PHPT and 20 age-matched healthy controls were included in the study. Fibrinogen, factors V, VII, VIII, IX and X activities, von Willebrand factor (vWF), antithrombin III (AT III), protein C, protein S, tissue plasminogen activator (t-PA) and tissue plasminogen activator inhibitor-1 (PAI-1), as well as common lipoprotein variables, were measured. The relationships between biochemical parameters and these hemostatic parameters were examinated. Results: Compared with the control subjects, platelet count, FVII, FX activities, and D-Dimer levels were signifi cantly increased in patients with PHPT (p < 0.001, p < 0.05, p < 0.001, and p < 0.05, respectively). Among the lipids, the levels of TC, TG and LDL-C were signifi cantly increased in patients with PHPT (p < 0.01, p < 0.001, p < 0.001, respectively) than those in controls. In patients with PHPT, we showed a positive correlation between urinary phosphorus excretion and factors VIII, IX, and X (r: 0.572, p < 0.01; r: 0.543, p < 0.01; r: 0.532, p < 0.01, respectively). F IX activity was positively correlated with TC (r: 0.463, p < 0.05) and LDL-C (r: 0.549, p < 0.01) There was a positive correlation between serum ALP and PAI-1 levels (r: 0.451, p < 0.05). ApoB was positively correlated with D-Dimer (r: 0.421, p < 0.05). We did not fi nd any signifi cant correlation between iPTH and serum calcium and the hemostatic parameters that we measured.
Introduction &
Primary hyperparathyroidism (PHPT) is associated with an increased cardiovascular mortality and morbidity rate [1 -3] . Proposed causes of increased cardiovascular risk associated with PHPT are hypertension [4] , left ventricular hypertrophy [5] , valvular and myocardial calcifi cation [6] , dysfunction in vascular reactivity [7, 8] , vascular structural changes [9] , arrhythmias [10] , insulin resistance and diabetes mellitus [11] , dyslipidemia [12] , increased body mass index (BMI) [13] , and increased serum urate levels [14] . Moreover, increased serum calcium and parathyroid hormone (PTH) levels are known to be correlated with the risk of premature death [15] . In a recent study, Kamycheva et al. reported that serum PTH predicts coronary heart disease (CHD) in subjects with calcium levels within the reference range [16] . However, the exact role of PTH and / or calcium in the development of cardiovascular disease (CVD) is still controversial [17, 18] . Plasma levels of several hemostatic variables have been associated with cardiovascular events in numerous prospective epidemiological studies [19, 20] . Meta-analyses have shown that the levels of fi brinogen [21] , fi brin D-dimer [22] , von Willebrand factor (vWF) [23] , and tissue plasminogen activator (t-PA) antigen [24] are signifi cantly associated with an increased risk of CHD. Other hemostatic parameters, including prothrombin fragment 1 + 2, fi brinopeptide A, factor VII (F VII), and factor VIII (F VIII) have been related to CVD, but the results are controversial [19] . To our knowledge, the infl uence of PHPT on hemostasis is unknown. In the literature, there is no study dealing with the changes in coagulation and fi brinolytic status in patients with PHPT. Therefore, the main purpose of this study was to investigate the markers of endogenous coagulation / fi brinolysis and to evaluate the relationships between these hemostatic parameters, serum lipid profi le and serum calcium and PTH in patients with PHPT. Elevated levels of hemostatic factors may represent activated coagulation and impaired fi brinolysis in the arterial wall [19] . On the other hand, a hypercoagulable state might increase the risk for thromboembolic complications and predispose to an increased prevalence of vascular disease. Patients did not receive a medical treatment (e.g. estrogen therapy) or did not have any known disease (e.g. diabetes mellitus, thyroid dysfunction, morbid obesity, coronary heart disease, collagen disease, liver cirrhosis, atrial fi brillation, or renal disease) that might affect blood coagulation or fi brinolysis, and, lipid profi le at the time of the study. Also, no medication known to infl uence the serum lipid concentration was administered. Twenty healthy age-and-sex-matched subjects (17 women and 3 men, mean age 49.8 ± 13.3 yr) were used as controls. Their biochemical values were within normal ranges. None of the controls were taking any drugs affecting the levels of serum calcium and PTH and hemostatic parameters and lipid levels. All participants including patients and control subjects were non-smokers, and there was no minor illness like viral infections or no family history of clotting disorders in patients and controls.
Design and Methods

& Patients and study design
Laboratory analysis
Blood was collected in the morning between 0800 -0900 h after an overnight fast to avoid the differences of diurnal variation, especially for hemostatic parameters. Plasma intact PTH levels were measured by automated two-site immunoradiometric assay (IRMA) (Immulite 2000 DPC, Diagnostic Product Corporation, 5210 Pacifi c Concourse, Los Angeles, USA). Serum total cholesterol (TC) was measured using a cholesterol oxidase enzymatic method; triglycerides (TG), by a glycerol oxidase enzymatic method; high density lipoprotein cholesterol (HDL-C), by a cholesterol oxidase enzymatic method in supernatant after precipitation with phosphotungstic acid-MgCl2. These routine analyses were carried out by autoanalyzer (Technicon AXON). Low density lipoprotein cholesterol (LDL-C) was calculated by the Friedewald ' s formule. For coagulation and fi brinolysis, a venous blood sample ( Protein C and Protein S activity assays were performed with ELISA method using commercial kits of Biopool International. VWF activity was determined by ELISA method using commercial kits of Imtec Immundiagnostica Gmbh. T-PA and PAI-1 assays were performed with ELISA using commercial kits of American Diagnostica. According to our hematology laboratory, normal ranges are 22 -39 mg / dL for AT III, 70 -150 % for vWF, 72 -160 % for protein C activity, 60 -150 % for protein S activity, 1 -20 ng / mL for t-PA Ag, and 20 -44 ng / mL for PAI-1 Ag.
Statistical analysis
Statistical analyses were performed by Student ' s t test for normal distribution data and Mann Whitney U test for not normal distribution data. In patient group, correlations among biochemical parameters and PTH and coagulation and lipid profi le were carried out using Pearson (normal distribution data) and Spearman (not normal distribution data) correlation analysis.
Results are cited as mean ± standard deviation. p < 0.05 was accepted signifi cantly.
Results & Table 1 summarizes the clinical characteristics and laboratory parameters in patients with PHPT and control subjects. As expected, the mean serum calcium, ALP, Chloride-to-phosphorus ratio (Cl / P ratio) and iPTH levels were signifi cantly higher in the patient group than those in controls, whereas serum phosphorus levels were signifi cantly decreased. Compared with the control subjects, platelet count, FVII, FX activities, and D-Dimer levels were signifi cantly increased in patients with PHPT (p < 0.001, p < 0.05, p < 0.001, and p < 0.05, respectively). Among the lipids, the levels of TC, TG and LDL-C were signifi cantly increased in patients with PHPT (p < 0.01, p < 0.001, p < 0.001, respectively) than those in controls. The other coagulation / fi brinolysis parameters and other lipoprotein profi le in patients with PHPT were not different from the controls.
In patients with PHPT, we showed a positive correlation between UPE and factors VIII, IX, and X (r: 0.572, p < 0.01; r: 0.543, p < 0.01; r: 0.532, p < 0.01, respectively) ( ᭹ ᭤ Fig. 1 ). F IX activity was positively correlated with TC (r: 0.463, p < 0.05) and LDL-C (r: 0.549, p < 0.01) There was a positive correlation between serum ALP and PAI-1 levels (r: 0.451, p < 0.05) ( ᭹ ᭤ Fig. 2 ). ApoB was positively correlated with D-Dimer (r: 0.421, p < 0.05) ( ᭹ ᭤ Fig. 3 ). We did not fi nd any signifi cant correlation between iPTH and serum calcium and the hemostatic parameters that we measured.
Discussion &
The role of PHPT in CVD is controversial. There is further strong evidence that PHPT may carry an increased risk for CVD [1, 6] . An increased prevalence of cardiac structural abnormalities such as left ventricular hypertrophy and valvular and myocardial calcification has been observed [5, 6] . To our knowledge, the present study is the fi rst to evaluate the hemostatic parameters in patients with PHPT. In the literature, early animal experiments with PTH intoxication revealed multiple thromboses at necropsy [25] and intravascular coagulation was found in hypercalcemic tumour animals [26] . Hilgard reported that experimental acute hypercalcemia in rats leads to a signifi cant shortening of the clotting time [27] . He suggested that acute hypercalcemia induces a hypercoagulable state, and thus favours thrombus formation in vivo .
There are few reports regarding the effects of PTH on platelet count and function in the literature [28, 29] . Findings are controversial. Remuzzi et al. reported that PTH inhibits human platelet function [28] . In contrast, Leithner et al. reported that PTH does not inhibit platelet aggregation in PHPT [29] . Increased and / or hyperactive platelets are one of the main fi ndings in hypercoagulable states and arterial thrombosis [30] . Moreover, Silverberg et al. reported that serum interleukin-6 (IL-6) levels are increased in PHPT compared to eucalcemic controls [31] . IL-6 stimulates thrombopoiesis [32] . In the present study, platelet count was signifi cantly increased in patients with PHPT compared to controls. This result may due to increased serum IL-6 levels seen in patients with PHPT. Also, increased platelet count in the patient group compared to controls may lead to a tendency to thrombosis and coagulation in patients with PHPT. F VII is a vitamin-K-dependent zymogen that is converted to its active form F VIIa in the presence of tissue factor. The F VIIa / tissue factor complex converts factors IX and X into their active forms, leading to thrombin generation and fi brin clot formation [33] . The Northwick Park Heart Study (NPHS) in London was the fi rst large-scale population study to report a signifi cant correlation between increased plasma F VII levels and the risk for subsequent CHD [34] . In other studies, elevated plasma F VII levels have been shown to be associated with arterial thrombosis and CHD [35, 36] . Ruddock and Meade suggested that F VII activity may be more strongly related to fatal events of CHD than to nonfatal events [37] . The investigators also suggested that increased F VII activity may infl uence outcome at the time of atherosclerotic plaque rupture and tissue factor release by enhancing thrombin production and consequent fi brin deposition and platelet aggregability. However, another prospective study failed to fi nd a signifi cant association between F VII and incident CVD [38] , and one large cross-sectional study also failed to associate F VII with prevalent CVD in middle-aged subjects [39] . In summary, coagulant factor VII clotting activity (F VIIc) was not over all confi rmed as an independent CVD risk factor and the significance of F VII in CHD remains unclear [35, 40] . In the present study, we found a signifi cant increase in F VII activity in patients with PHPT. Increased F VII activity may lead to a tendency to hypercoagulable state and arterial thrombosis. Also, increased F VII activity is partly due to an elevation of the hemostatic balance by interactions between coagulation factors and lipoproteins [35] . A signifi cant correlation between F VIIc levels and TGs as well as TC has been shown in several studies [41, 42] . On the one hand, higher F VIIc levels in hyperlipidemic patients may be due to enhanced synthesis of F VII or a larger proportion of the activated form of F VIIc [42, 43] . The correlation between F VIIc and lipids may be explained by the binding of F VII to TG-rich particles [44] . Hovewer, in the present study, we did not fi nd a correlation between F VII activity and lipoprotein levels in patients with PHPT. FX plays an important role in the normal coagulation mechanism: it is activated by FIXa and its cofactor, or by FVIIa and tissue factor. Once it is activated, FXa catalyses the conversion of prothrombin to thrombin. In multivariate analyses in previous epidemiological studies, high plasma levels of FVII and FX were both independent risk factors for coronary artery disease or recurrent myocardial infarction, mainly in connection with hypertriglyceridemia [45, 46] . Hoffman et al. reported that FX was positively correlated with TC and LDL-C in healthy young women, and FX was positively correlated with TG, TC and LDL-C in healthy young men [46] . Okura et al. found that serum TG levels were signifi cantly associated with the plasma activities of FVII and FX [47] . Moreover, FXa directly stimulates proliferation of rat aortic smooth muscle cells independently from thrombin formation [48] . Koo et al. reported that FXa induces mitogenesis of coronary artery smooth muscle cell via activation of proteaseactivated receptor-2 [49] . In our study, increased FX activity in PHPT may lead to a tendency to thrombosis and / or cardiovascular events. It has been shown that fi brinogen, PAI-1 and D-Dimer are all associated with CHD [50] . In atherosclerotic plaques, the thrombin converts fi brinogen to fi brin, which is lysed by plasmin, producing fi brin degradation products like D-Dimer [51] .
However, D-Dimer shows only a weak correlation with the severity of CHD [52] . In a very recent study, Tzoulaki et al.
reported that D-Dimer and fi brinogen, but not other markers of coagulation and fi brinolysis, were associated with progressive peripheral atherosclerosis and since D-Dimer and fi brinogen were acute phase reactants, infl amation is more likely to be the case rather than hypercoagulation [19] . In the present study, we found a signifi cant increase in D-Dimer levels in patients with PHPT. Increased D-Dimer levels may lead to a tendency to thrombosis which is crucial in cardiovascular events. However, the value of increased D-Dimer levels as a risk factor is controversial. Moreover, in our study, D-Dimer was positively correlated with apo B. In the literature, it has been shown that a strong association exists between lipids (especially TG-rich lipoprotein) and fi brinogen, PAI-1, and activated F VII levels [53] . Disorders of the fi brinolytic system are also a possible causal mechanism in the development of the hypercoagulable state in relation to both arterial and venous thrombosis [54] . In arterial disease, the principal mechanism for the impaired fi brinolysis seen frequently in patients with CHD is increased PAI-1 activity in plasma. Thogersen et al. reported that although PAI-1 levels appeared to positively correlate with the incidence of fi rst myocardial infarction, this association was not statistically significant after adjustment for traditional cardiovascular risk factors (hypertension, diabetes mellitus, lipids, and BMI) [55] . At present, there are no compelling epidemiological studies that defi ne PAI-1 as a clear risk factor for arterial thrombotic events [33] . In the present study, we did not fi nd any signifi cant change in PAI-1 levels in patients with PHPT. However, in our study, PAI-1 levels were positively correlated with serum ALP levels. A high prevalence of lipid abnormalities (increased TC, TG, LDL-C, decreased HDL-C, and elevated atherogenic index) has been reported in patients with PHPT [12, 56] . These alterations were inversely correlated to the serum PTH level [57] . It has been shown that patients with PHPT have an impairment of glucose metabolism. The metabolic disturbances accompanying insulin resistance could contribute to moderately increased TG and decreased HDL-C levels in PHPT in accordance with what is otherwise seen in subjects with insulin resistance [56] . Elevated serum TG correlates with the incidence of CVD [58] . TGs have been found to increase coagulation factor activity and to decrease fi brinolysis [57] . In the present study, we found increased TC, TG, and LDL-C levels in the patients with PHPT. This condition may represent a situation with increased cardiovascular risk and the higher thromboembolic potential. Moreover, in our study, F IX activity was positively correlated with TC and LDL-C. We did not fi nd any association between plasma PTH levels and lipid profi le. Interestingly, in the present study, we found positive correlation between UPE and factors VIII, IX and X in PHPT patients. As UPE was considered as a marker of PTH activity in kidneys, the increase in these coagulation factors may be due to the severity of PHPT. In the present study, we don ' t know about short-and long-standing PHPT. Because all of the patients were diagnosed fi rst time in our clinic. This situation is a limitation of our study.
In conclusion, we found some important differences in the hemostatic parameters between the patients with PHPT and healthy controls. Increased platelet count, F VII and FX activities and D-Dimer levels in patients with PHPT represent a potential hypercoagulable state, which might augment the risk for atherosclerotic and atherothrombotic complications. This condition may contribute to the excess mortality due to CVD seen in patients with PHPT. Therefore, further investigations may be planned to clarify the condition.
